Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end platform that spans AI‑driven RNA design through manufacturing and high‑resolution sequencing validation. Eclipsebio said Terrain’s machine‑learning RNA analytics complement its sequencing‑first capabilities, with the combined offering aimed at iterative RNA construct design, structure/translation measurement and manufacturing robustness assessment. Eclipsebio’s CEO positioned the deal as advancing a ‘design‑to‑manufacture’ vision for RNA therapeutics, enabling earlier design input and deeper validation for drug developers. The acquisition underscores the intensifying consolidation of RNA design, analytics and manufacturing expertise as demand for RNA modalities grows.